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Cell migration and chimerism are observed more 
The events following organ transplantation require dramatically after liver transplantation, which may ex-
a reciprocal cell interaction which includes both the plain why the liver is a more tolerogenic organ than the 
conventional host-versus-graft reaction and a graft- kidney. In fact, with all successful transplantations, 
versus-host component. With all successful trans- regardless of which organ is involved, both graft and 
plantation, both graft and recipient become genetic recipient become genetic composites, bearing the cells 
composites. Where donors were available, chimerism of both individuals. With all transplanted organs, the 
has been confirmed in 30-year kidney-recipient survi- interaction of the two cell populations can be envi-
vors, as well as in several liver and lung reCipients: A sioned as a teeter-totter in which each side can abro-
majority of liver recipients have been able to acqwre gate the immunologic effect of the other in what we 
an immunosuppressant-free state after ll-~ear sur~K4<-have called mutual natural immunosuppression (1, 4, 
vival. Animal models ~uggeUt that donor-denved cells 6). This reciprocal interaction effectively ''blindfolds'' 
may exert a tolerogemc effect. C 1888 Academic Pre-. IDe. the major histocompatibility complex (MHC) effect and 
INTRODUCTION 
A transplanted organ was typically perceived, until 
recently, as an island in a hostile recipient sea (Fig. 1). 
We have referred to this hypothesis as "the one-way 
paradigm." A different perspective then emerged which 
elucidated the mechanisms responsible for organ-graft 
acceptance. This was based on the novel observations 
that donor leukocytes migrated from these trans-
planted organs and survived for long periods through-
out the body of the recipient (1-6). This discovery ne-
cessitated the development of a new paradigm (7). 
With the new paradigm, the events following renal 
(or other organ) transplantation were seen as a two-
way cell interaction which includes both a conventional 
host-versus-graft reaction and a graft-versus-host com-
ponent (Fig. 2). Passenger leukocytes from the graft 
were multilineage and of bone marrow origin, which 
made the placement of the organ allograft the equiva-
lent of a mini-bone marrow transplantation. At the vast 
interface between the coexisting cell populations, we 
suggested that changes occurred in the way each cell 
cohort viewed the other and that these changes elicited 
the development of suppressor and veto cells, enhanc-
ing antibodies, and observed changes in the cytokine 
profile. 
1 To whom correspondence and reprint requests should be ad· 
dressed. Dept. of Surgery, 3601 Fifth Ave., 5C Fatk Clinic, University 
of Pittsburgh, Pittsburgh, PA 15213. 
explains why tissue matching, which is crucial for suc-
cessful clinical bone marrow transplantation, does not 
accurately predict the outcome after the grafting of a 
whole organ. 
The relationship of this concept to that of acquired 
tolerance, as described by Billingham et ai. (8, 9), is 
easy to understand. Their experimental model was im-
balanced because the immune system of their recipient 
was immature (Fig. 3). Imbalance can also be achieved 
genetically in the F 1 hybrid parent-to-offspring animal 
model and iatrogenically by recipient-cytoablation with 
irradiation or cytotoxic drugs. Then, as with bone mar-
row transplantation, if the immunocytes in the trans-
planted organ are sufficiently numerous, as in the in-
testine, one of the censoring limbs is absent and graft-
versus-host disease (GVHD) follows (10). If neither the 
recipient nor the graft is leukocyte-depleted, however, 
it is possible to perform intestinal or even multivisceral 
transplantation without an exorbitant risk of GVHD 
(11,12). Thus, the difference between bone marrow and 
whole-organ transplantation is merely a reflection of 
the therapeutic strategies used. Bone marrow trans-
plantation (Fig. 3) is conceptually derived from the 
original Billingham et ai. model in that one of the reac-
tion limbs is dysfunctional or disabled. This leaves the 
recipient GVHD-prone and requires MHC matching for 
survival. Success, in this model, is called tolerance. In 
contrast, the treatment strategy for whole-organ trans-
plantation leaves both cell populations intact (Fig. 2), 
thereby eliminating MHC matching as a prerequisite 
for success and largely eradicating the threatofGVHD. 
This is commonly referred to as "graft acceptance." 
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FIG. I. One-way paradigm (organ). In nonconditioned recipients, 
transplanted whole organs were generally considered as defenseless 
ialands in the hostile environment of the host's alloreactive cells. This 
unidirectional immune reactivity led to unrestrained HVG reaction 
(rejection). 
IMMUNOSUPPRESSIVE REGIMENS 
FOR WHOLE ORGANS 
The two-way paradigm explains the success of the 
empirically derived therapeutic dogma upon which the 
field of whole-organ transplantation is based. The 
dogma calls for baseline therapy with one or two im-
munosuppressant drugs, secondary adjustments as 
needed with steroids, followed by individualized reduc-
tion to maintenance levels which are required to sus-
tain stable graft function. Although the baseline thera-
peutic agents, beginning with azathioprine (subse-
quently cyclosporine and tacrolimus), have improved 
through the years, the strategy has remained the same 
over the past three decades. 
Many aspects of immune recognition and response 
were subsequently clarified. These have included the 
role of antigen-presenting cells, the necessity for a cos.".-" 
timulatory molecule, the role of accessory molecules, ~ 
and the way cytokines controlled clonal expansion of 
the helper and cytotoxic T cells which mediate allograft 
destruction. Moreover, the diversity of agents with 
which long-term or permanent graft survival could be 
induced in experimental animals with a short course 
of therapy has been surprising no matter what the level 
of intervention in the immune process, i.e., from the 
most proximal inhibition by CTLA.lg to the distal in-
terdiction of the action of normally formed cytokines 
by rapamycin. These nonspecific drugs became specific 
only by virtue of the presence of donor antigen (13). 
An Early Clue of Spontaneous Chimerism 
A clue to what was happening was obtained from 
studies of a group of patients who underwent successful 
renal transplantation at the University of Colorado in 
1962 and 1963. Both the donors and these pioneer re-
cipients underwent preoperative skin tests to deter-
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FIG. 2. Two-way paradigm (organ). Bidirectional mechanism of 
whole-organ graft acceptance involves a GVH component mediated 
by the bone marrow-derived donor leukocytes from the graft and the 
response of the host's immune cells referred to as HVG reaction. For 
standard whole-organ clinical transplantation, the recipient is not 
preconditioned. 
mine delayed hypersensitivity reaction to tuberculin, 
histoplasmin, and other antigens. Recipients who were 
negative to these antigens preoperatively, but whose 
donors were positive, acquired the positive skin tests 
only if the kidney transplantation was successful, but 
not if it failed (14, 15). The adoptive transfer of immu-
nity became evident and implied that the donor leuko-
cytes had survived and were functional. At the time, 
however, the kidney was considered to be a leukocyte-
.,...---- GVH ---.... 
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FIG. 3. One-way paradigm (bone marrow)_ The unidirectional 
paradigm of bone marrow transplantation, where the recipient is 
rendered defenseless by cytoablative conditioning, leads to a GVH 
reaction. A similar outcome was also witnessed in the Billingham et 
al. experimental model following bone marrow transplantation into 
immunologically incompetent (neonate) animals. 
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poor organ, and the implication that donor cells must 
have migrated was ignored. 
THE DISCOVERY 
about discontinuation of immunosuppression. 
with the foregoing information, a deliberate 
weaning program was begun in other patients 
were 5 to 10 years postliver transplantation (17). 
results suggest that the majority of liver recipients 
In 1992, 5 of these original kidney recipients, whose viving at least a decade can eventually acquire a ............ ~~KKtK 
grafts still functioned normally, were studied for chi- free state (18). 
merism in their blood, skin, and lymph nodes. Their It is far more dangerous to attempt drug dlbfClllltignm~ 
donors, who still were alive, cooperated. All five of the ance in kidney recipients, but it is well kn.own to 
recipients were found to be chimeras (5). The identity of feasible in isolated cases. Our 10 patients with the . 
the donor and recipient cells was established by either prolonged follow-up include the recipient of the lon"f~~D 
cytostaining, allowing the donor cells to be visualized continuously functioning kidney allograft in the 
in the tissues, or by polymerase chain reaction, which and constitute about two-thirds of those from the 
identified donor DNA Markers used were donor-spe- experience through January 1964 (12) who are still sur-
cific HLA alleles on chromosome 6 and the SRY region viving. When tested in 1992, all had donor-specific non~D 
of the Y chromosome in female recipients of male or- reactivity which was absolute in 8 and pronounced fu 
gans. Using donor-specific HLA alleles as markers, chi- the other 2. Of these 10 patients, all now more thall 
merism was also found in all 22 liver recipients who 31 years posttransplantation, 5 are off immunosu~ 
were studied from 10j to 21 years after liver replace- pression and have been for 2, 2i, 15,29, and 31 years, 
ment, many with more comprehensive sampling (in- respectively (19-21). Three of these 5 were HLA-mis-
eluding biopsies of heart, bone marrow, and intestine) matched with their donors. 
than that in the kidney recipients (4). Additionally, in < 
9 of these 22 patients who were female recipients of· .. ·''' ... 
male livers, chimerism was also confirmed by the pres-
. DONOR LEUKOCYTE AUGMENTATION 
ence ofY chromosomes (2). 
The presence of chimerism was subsequently estab-
lished in recipients of thoracic organs (4, 16). In an 
important study, Keenan et al. (16) stratified 15 lung-
transplant recipients followed 1 to 5 years into a favor-
able group of 8 with no bronchiolitis obliterans and 7 
who had the ominous finding of chronic rejection. The 
patients without bronchiolitis obliterans had dense chi-
merism, which was positive in 8/8 lymph nodes, 7/8 
skin biopsies, and 6/8 blood samples. Furthermore, 
lower levels of donor cell chimerism were variably de-
monstrable in the less favored group. Using irradiated 
cryopreserved splenocytes as stimulators, donor-spe-
cific nonreactivity was demonstrated in all but 1 of the 
densely chimeric recipients, but in only 2 of those in 
the less favored group. 
Can Chimeric Organ Recipients Be Drug·Free? 
Envisioning the engraftment of donor cells after 
whole-organ transplantation in the same context as 
that of a mini-bone marrow infusion prompted the 
question of whether some of these patients could have 
their immunosuppression stopped altogether. At the 
time of the liver chimerism study in early 1992, there 
were 43 patients who had survived for 12 to 23 years 
posttransplantation. Six of them had long since discon-
tinued therapy (4), and subsequently 4 additional pa-
tients have been added to this list. Presently, 10 of the 
remaining 43 long-term survivors have been drug-free 
for 2 to 16 years. As the longest survivors in the world, 
this cohort of patients has taught us important lessons 
If our hypothesis of the mechanism of graft accep-
tance is correct, it should be possible to safely facilitate 
this process by adding unaltered donor bone marrow 
perioperatively to the minimal dose of the so-called pas-
senger leukocytes contained in a whole-organ allograft. 
Such a trial is well underway in Pittsburgh (22) and 
now includes 89 patients entered between December 
1992 and February 1995. Donor bone marrow cells, 
obtained from cadaveric vertebral bodies, were not T-
cell depleted or modified prior to infusion. Subsequent 
to organ placement, 3-5 x 108 cellslkg were infused 
into nonconditioned recipients who were then main-
tained on routine immunosuppression with tacrolimus 
and prednisone. No complication of bone marrow infu-
sion was observed in any of the 89 primary whole-organ 
transplant recipients and their convalescence was 
rapid. The cumulative risk of rejection was similar in 
both bone marrow-augmented and non augmented re-
cipients and there was no incidence of clinical GVHD. 
The results of this study are summarized in Table 1. 
EXPERIMENTAL VERIFICATION 
Phenomenology 
The clinical aspect of these developments has sup-
ported the establishment of the two-way paradigm. An-
imal experimentation has provided much additional in-
formation. In immunosuppressed rats, Demetris et al. 
(23) have shown how the migratory cells begin to home 
to the central lymphoid organs within minutes after 
whole-organ transplantation where they pause for 2 or 
, 
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TABLE 1 
Function and Actuarial I-Year Graft Survival of Bone Marrow-Augmented 
and Nonaugmented Whole-Organ Transplant Recipients 
Organs 
transplanted n 
Graft. 
survival° 
(%) 
Bilirubin 
(mg/dl) 
Function (f ± SO) 
Creatinine 
(mg/dl) 
Cardiac 
output 
(liters/min) 
FEVl 
(liters) 
Bone marrow-augmented 
Liver 34& 
Kidney 40" 
Heart 10 
Lungs 05 
31 (91) 
39 (98) 
08 (80) 
05 (l00) 
0.8:± 0.6 
1.7 ± 0.6 
6_0:± 1.7 
2.0 ± 2.0 
Liver 33 26 (79) 
18 (86) 
06 (l00) 
Controls 
0.7 :± 0.3 
Kidney 21d 2.2 :± 1.5 
Heart 04 6.3 ± 3.2 
Lung 01 o 
• Actuarial I-year graft. survival. 
6 One type I diabetic also received pancreatic islets, not insulin-free. 
• Nineteen type I diabetics also received either whole-organ pancreas (n = 13) or isolated pancreatic islets (n = 6); 11 patients (all 
recipients of pancreata) are insulin-free. 
d four type I diabetics also received whole-organ pancreas transplants; 2 are currently off insulin. 
3 weeks before becoming generalized. The migration 
is multilineage, following the same routes as that of 
syngeneic cells, i.e., B cells to B-cell follicles in lymph 
nodes, T cells to the T-cell areas, and the dendritic cells 
and macrophages to their normal areas of localization. 
The same events have also been documented in mice 
(24). A bonus in the mouse experiments, however, was 
that permanent survival of liver allografts occurred 
without the need for any treatment and across all MllC. 
disparities. Similar to our observations in rats, the chi-! 
meric mouse liver recipients could then accept donor-
strain skin and heart, but not grafts from third-party 
animals. 
Fundamental Mechanisms 
How the migratory leukocytes induce tolerance is the 
question currently being investigated by the cellular 
immunologists in Pittsburgh. The initial observations 
indicate that a subset of donor-derived dendritic cells 
may play a key role in the induction of donor-specific 
tolerance. The mouse liver was selected as the source 
of nonparenchymal leukocytes (NPCs). After dis-
carding the hepatocytes and duct cells, about 107 NPCs 
could be obtained from each liver (25). These NPCs 
"were cultured in GM-CSF -enriched medium which 
a selective growth advantage to leukocytes of my-
. K:"~ .. ___ 1ineage (26). After 4-5 days of culture, 2 x 106 
with dendritic morphology and surface phenotype 
.. : ....... UJ'u be identified (25). A subpopulation of these cells 
--------------.. ---_. -. 
formed clusters on the bottom of the culture wells. 
Loosely adherent cells were harvested and further cul-
tured and studied according to the methods described 
by Inaba et al. (26). Although they had the phenotype 
and function of precursor dendritic cells, it was difficult 
at first to prove their dendritic leukocyte origin because 
it was impossible to drive them to maturation, even 
with the addition of interferon-'Y and tumor necrosis 
factor. They had poor allostimulatory function, ex-
pressed low levels of MHC class II antigen, and were 
avidly phagocytic (25). 
This impasse was broken when the culture wells 
were coated with Type I collagen, thus simula.ting the 
natural microenvironment of liver where mature den-
dritic cells are normally known to reside. Under these 
conditions, the precursor cells in the wells promptly 
assumed the properties of mature dendritic cells, now 
expressed high levels of MHC class II antigen, and ac-
quired potent allostimulatory activity. The question of 
whether these unusual cells would mature and express 
class II antigen in vivo was investigated by injecting 
the purified precursor cells from B10.BR livers into the 
footpad of fully allogeneic B10 mouse recipients. The 
cells migrated promptly to the T-cell areas of the cen-
tral lymphoid organs where they were easily pheno-
typed as donor and shown to express high levels of class 
II antigen (25) . 
It has been demonstrated recently how these puta-
tively tolerogenic immature dendritic cells, after they 
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FIG. 4. Two-way paradigm (bone marrow). Bidirectional para-
digm in bone marrow transplantation where cytoablation is used 
to precondition the recipient. However, complete elimination of the 
recipient leukocyte population is almost never possible (see text). 
Note that the result in the recipient is a mirror-image version of 
whole-organ transplantation. 
migrate from transplanted organs, establish residence 
in multiple active niduses within the recipient tissues 
creating widespread and persistent cellular oases (27, 
28). These remarkable findings suggest a mechanism 
for perpetuation of the migratory dendritic cells and 
the means by which these cells may exert a tolerogenic 
effect. 
THE TWO-WAY PARADIGM: BONE MARROW 
Although the vast gap between the fields of bone 
marrow and whole-organ transplantation was bridged, 
one clarifying detail was missing before the linkage 
could be considered seamless. Complete donor chime-
rism was long assumed to be the objective of bone mar-
row transplantation, and if this were true, the one-
way paradigm would still apply. However, Thomas and 
others have recently shown that a trace population of 
recipient leukocytes can be detected with sensitive mo-
lecular techniques in recipients who have received bone 
marrow from opposite sex donors (29, 30). Thus, the 
veto and other accessory events at the cellular interface 
are the same, in principle, with bone marrow as with 
organ transplantation, differing only in their role in 
the David/Goliath mismatch (Fig. 4). With this final 
piece of information, the story was complete. 
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